Skip to main content
. 2022 Jun 22;30(11):3341–3357. doi: 10.1016/j.ymthe.2022.06.011

Figure 5.

Figure 5

MECOM depletion suppressed CSC-associated factors

(A and B) ADV-CRISPR-SaCas9 with MECOM depletion (MECOM-KO) was intratumorally injected into the PDX models. After 2 days, the tumors were isolated from the LUSC006, LUSC018, and LUSC021 cases for gene editing analyses using T7EI assay (A: LUSC006, LUSC018, and LUSC021) and Sanger sequence (B: LUSC021).

(C–E) After 24–28 days, the treated tumors were isolated from the LUSC006, LUSC018, and LUSC021 cases for western blot and immunohistochemistry assays. Western blots (C) show MECOM, SOX2, ABCG2, CD44, and β-actin expression in the tumor samples of LUSC006, LUSC018, and LUSC021 models with depleted MECOM (MECOM-KO). β-Actin was used as the loading control. The numerical value under the band shows densitometric analyses of the indicated protein expression, compared to the corresponding control, which was normalized as “1.0.” Photographs (D) and IRS scores (E) of MECOM, CD44, and ABCG2 in the tumor samples of LUSC006, LUSC018, and LUSC021 models with MECOM-depleted ADV (MECOM-KO) by immunohistochemistry analyses. Scale bars, 50 μm. ∗p ＜ 0.05, unpaired 2-tailed t test.